ofloxacin has been researched along with Peptic Ulcer in 3 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H." | 9.15 | Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. ( Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A, 2011) |
| " The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H." | 5.15 | Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. ( Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, KH | 1 |
| Chung, WC | 1 |
| Lee, KM | 1 |
| Paik, CN | 1 |
| Kim, EJ | 1 |
| Kang, BK | 1 |
| Oak, JH | 1 |
| Jung, SH | 1 |
| Ermis, F | 1 |
| Akyuz, F | 1 |
| Uyanikoglu, A | 1 |
| Kurt, R | 1 |
| Pinarbasi, B | 1 |
| Nazik, H | 1 |
| Kaymakoglu, S | 1 |
| Mungan, Z | 1 |
| Buzás, GM | 1 |
1 review available for ofloxacin and Peptic Ulcer
| Article | Year |
|---|---|
[Helicobacter pylori - 2012].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Dr | 2012 |
2 trials available for ofloxacin and Peptic Ulcer
| Article | Year |
|---|---|
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug | 2011 |
Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; D | 2011 |